Study Shows How Steroid Nasal Sprays May Impact COVID-19

Translate to Spanish or other 102 languages!

A Cleveland Clinic Study found that patients who regularly use steroid nasal sprays are less likely to develop a severe case of COVID-19. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Cleveland Clinic – A Cleveland Clinic Study found that patients who regularly use steroid nasal sprays are less likely to develop a severe case of COVID-19. It also reduced their risk for hospitalization, ICU admission and death.

“This does not mean that people should use nasal sprays to treat COVID-19 or to prevent COVID-19. You need a randomized control trial to do that and an approval by the FDA, so until then, it is not indicated to treat COVID-19,” explained Joe Zein, MD, pulmonologist for Cleveland Clinic.

Dr. Zein authored the study and said they found patients who used intranasal corticosteroids prior to COVID-19 illness were 22% less likely to be hospitalized, 23% less likely to be admitted to the intensive care unit, and 24% less likely to die from COVID-19 during hospitalization.

- Advertisement -

Dr. Zein said since the nose is the main entry point for the virus, it’s important to wear your mask properly.

“Many people you see wearing a mask don’t have their nose covered. The nose is the most important part, and they need to cover it. Otherwise, there is no point in using a mask,” he said.

Dr. Zein said they are still trying to understand why the nasal sprays seem to help reduce severity of disease. However, it appears they decrease the ACE2 receptors in the nose, making it harder for the virus to enter cells and spread.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.
- Advertisement -